UA140097U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, folic acid, interleukin 6 (IL-6), C-reactive protein (PSP), glycosaminoglycans (GAG). With a homozygous carrier of 786-CC, endothelin levels> 10 ng / ml, folic acid <6 ng / ml, IL-6> 10 ng / l, PSA> 6 mg / l, GAG> 28 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (eMO5 1786C), the content of endothelin, folic acid, interleukin b (IL-6), C-reactive protein (CRP), is determined in the patient's blood serum. of glycosaminoglycans (GAG) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-b" 10 ng/l, SRP "b mg/l, GAG" 28 μmol/l predict development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMmo5 1786C gene polymorphism is determined, the content of endothelin, folic acid, IL-6, SRP, GAG is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-6 210 ng/l, SRP "6 mg/l, GAG x" 28 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient L., 60 years old, was admitted to the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of endothelin, folic acid, IL-6, SRP, and GAG were determined in the serum. A homozygous carrier of 786-SS was established, the levels of endothelin - 22 ng/ml, folic acid - 3.5 ng/ml, IL-6-25 ng/l, SRP - 15 mg/l, GAG - 43 μmol/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (6ЕМО5 T786С), the content of endothelin, folic acid, interleukin 6 (IL-b), C-reactive protein (SRP), glycosaminoglycans (GAG) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, GAG 528 μmol/l predict the development of osteoarthritis.